SOURCE: ChromoCure, Inc.

January 08, 2010 11:56 ET

ChromoCure Releases Investor Guidance on Short-Term Business Objectives

RENO, NV--(Marketwire - January 8, 2010) - ChromoCure, Inc. (PINKSHEETS: KKUR) announced today interim stockholder guidance on upcoming events. Full details on the below items will be released in the coming days.

Release of Pre-Clinical Testing and Study with Major Cancer Clinic

The company will release the test and pre-clinical study results it performed in collaboration with a world-renowned cancer clinic for its original Version 1 scanner. These results now become highly relevant given the new credibility of the chromosomal theory of cancer provided by the Mayo Clinic's recent research.

New International Initiatives:

Due to recent significant developments within the mainstream scientific community, the company will soon announce new business development and marketing programs. The Company's technology is designed around the chromosomal theory of cancer. The Company has long known the validity of this cancer theory and welcomes new research published by the world-recognized Mayo Clinic. As shareholders will recall from recent announcements, the Mayo Clinic recently proved the chromosomal basis of cancer. Their research confirms the chromosomal theory of cancer and immediately establishes the company's technology in the forefront of both cancer detection and research. ChromoCure's proprietary CS200 Chromosomal Scanner system and related technology is specifically designed to target the unique chromosomal characteristics demonstrated in the Mayo Clinic research. Detecting the unique chromosomal signature of cancer yields an effectively 100% accurate method of detecting all forms of cancer at all stages.

Scientific White Paper

The company will release a comprehensive scientific White Paper describing its technology and the chromosomal basis of cancer.

New Initiatives on Therapeutics

Because the company's systems detect the single characteristic found in 100% of all cancers at all stages we are able to precisely measure the exact stage and level of cancer progression across all cells within a sample. Due to our understanding of cancer, its mechanisms, and progression characteristics, the company believes its technology invites unique approaches to non-toxic and non-invasive cancer therapy and elimination. The company will soon announce new initiatives for its detection technology as applied to therapeutics.

About ChromoCure

ChromoCure develops and provides proprietary cancer detection systems. The Company owns its technology and provides its systems on a revenue sharing basis. The Company's proprietary ChromoCure CS200 Chromosomal Scanner system measure the unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company believes its technology has an effective accuracy of 100% for all cancers at all stages. The Company believes its technology superior and will become the gold standard for cancer detection worldwide.

The Company's technology and cancer expertise also suggest non-toxic and non-invasive approaches to cancer therapy and cure research. The Company will release progress reports on these initiatives from time to time.

Safe-Harbor Statement

This release contains statements or projections regarding future performance that is forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. The company's filings contain various RISK FACTORS (and are incorporated herein by reference) and should be read before any investment decision.

Contact Information